Abstract: The present disclosure provides, in part, compositions and methods for enhancing the efficacy of immune checkpoint blockade therapy in a subject. Methods for identifying subjects that are appropriate for immune checkpoint blockade therapy are also provided.

Abstract: A method for treating cancer in an individual comprises administering to the individual a therapeutically effective amount of a PCSK9 inhibitor. The method may further comprise administering to the individual at least one immune checkpoint inhibitor.

Abstract: Provided herein are methods for treating cancer in a subject comprising administering an ICB therapy to a subject having cancer, wherein the subject's cancer comprises one or more mutations in two or more genes associated with responsiveness to immune checkpoint blockade (ICB).

Abstract: The present invention provides methods for using the level of caspase 3 activity for determining or prognosticating likelihood of cancer recurrence or relapse in a patient after the treatment for cancer. The present invention also provides methods for treating cancer in a patient using a caspase 3 inhibitor in conjunction with a conventional cancer treatment.

Abstract: The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a hypoxic cell. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a cell, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods.

Abstract: A reset control device for an electronic device having a battery for providing operating power for a system circuit is provided. The reset control device includes a signal generating unit for generating a control signal, and a control module installed in the battery and coupled to the signal generating unit for disconnecting a power supply link between the battery and the system circuit for a predetermined duration and recovering the power supply link, when the control signal conforms to a predefined rule, so as to reset the system circuit.

Abstract: A reset control device for an electronic device having a battery for providing operating power for a system circuit is provided. The reset control device includes a signal generating unit for generating a control signal, and a control module installed in the battery and coupled to the signal generating unit for disconnecting a power supply link between the battery and the system circuit for a predetermined duration and recovering the power supply link, when the control signal conforms to a predefined rule, so as to reset the system circuit.

Abstract: A method for reducing leakage of a delivery formulation from a target tissue via a damaged blood vessel during and after administration of the delivery formulation is provided. The method includes the steps of: (a) providing a delivery formulation comprising a blocking agent and one or more vectors encoding one or more polypeptides, wherein the delivery formulation is in a liquid form; and (b) administering the delivery formulation to a target tissue in a subject, wherein the administering results in the viscosity of the blocking agent increasing to at least about 100 cP, whereby leakage of the delivery formulation from the target tissue either during or after administration of the delivery formulation is reduced.

Abstract: The present invention provides caspase modulators in a wide variety of therapeutic applications. Some aspects of the present invention provide methods for using caspase modulators in treating tumor, promoting wound healing, and producing induced pluripotent stem cells.

Abstract: The presently claimed subject matter provides conditionally replication competent adenoviral vectors that confer selective cytotoxicity on cells expressing HIF-1 by infecting cells that allow HIF-1 inducible promoters present within the vectors to function. Also provided are compositions and host cells based upon the vectors, as well as methods of propagating and using the vectors. The presently claimed subject matter further provides a method of inhibiting tumor growth by co-infecting cells in a tumor with a conditionally replication competent adenovirus vector in conjunction with a replication deficient adenovirus vector.

Abstract: The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a hypoxic cell. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a cell, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods.

Abstract: The presently disclosed subject matter provides vectors that encode small interfering RNAs (siRNAs) designed to down regulate the expression of hypoxia-inducible genes in a cell. Also provided are compositions and host cells based upon the vectors, as well as methods of using the vectors. The presently disclosed subject matter further provides a method of inhibiting tumor growth infecting cells in a tumor with an adenovirus vector that encodes an siRNA directed against the hypoxia-inducible factor 1? (HIF-1?) gene.

Abstract: A method for controlling in vivo heat-inducible gene expression for provision of therapeutic polypeptide. The method includes the steps of: (a) providing a construct comprising a polynucleotide encoding a therapeutic polypeptide, wherein the polynucleotide is operatively linked to a heat-inducible promoter; (b) administering the construct to a warm-blooded vertebrate at a site at or near the tumor; and (c) applying heat to the site at or near the tumor to express the therapeutic polypeptide, whereby anti-tumor activity is observed.

Abstract: A method for controlling in vivo heat-inducible gene expression for provision of therapeutic polypeptide. The method includes the steps of: (a) providing a construct comprising a polynucleotide encoding a therapeutic polypeptide, wherein the polynucleotide is operatively linked to a heat-inducible promoter; (b) administering the construct to a warm-blooded vertebrate at a site at or near the tumor; and (c) applying heat to the site at or near the tumor to express the therapeutic polypeptide, whereby anti-tumor activity is observed.

Abstract: The presently claimed subject matter provides conditionally replication competent adenoviral vectors that confer selective cytotoxicity on cells expressing HIF-1 by infecting cells that allow HIF-1 inducible promoters present within the vectors to function. Also provided are compositions and host cells based upon the vectors, as well as methods of propagating and using the vectors. The presently claimed subject matter further provides a method of inhibiting tumor growth by co-infecting cells in a tumor with a conditionally replication competent adenovirus vector in conjunction with a replication deficient adenovirus vector.

Abstract: A method for controlling in vivo heat-inducible gene expression for provision of therapeutic polypeptide. The method includes the steps of: (a) providing a construct comprising a polynucleotide encoding a therapeutic polypeptide, wherein the polynucleotide is operatively linked to a heat-inducible promoter; (b) administering the construct to a warm-blooded vertebrate at a site at or near the tumor; and (c) applying heat to the site at or near the tumor to express the therapeutic polypeptide, whereby anti-tumor activity is observed.